Earnings Releases

Alpha Teknova, Inc. reported first quarter ended March 31, 2024 results: revenue $9.3 million, net income negative $8.1 million, EPS negative $0.20 per diluted share. Guidance reaffirmed.

“Teknova Reports First Quarter 2024 Financial Results First quarter 2024 total revenue was $9.3 million, up 2% from prior year”

Texas Community Bancshares, Inc. reported three months ended March 31, 2024 results: net income net loss of $2.7 million, EPS $(0.90).

“Texas Community Bancshares, Inc. issued a press release announcing its unaudited consolidated financial results for the three months ended March 31, 2024 and 2023.”

Lafayette Square USA, Inc. reported financial results for the fiscal quarter ended March 31, 2024.

“A copy of a results presentation summarizing certain financial, performance and human capital information for the fiscal quarter ended March 31, 2024 is attached as Exhibit 99.1 to this Form 8-K.”

Centessa Pharmaceuticals plc reported the first quarter ended March 31, 2024 results: net income $38.0 million.

“Centessa Pharmaceuticals plc (the “Company”) announced its financial results for the quarter ended March 31, 2024”

NET Power Inc. reported financial results for the quarter ended March 31, 2024.

“On May 13, 2024, NET Power Inc., a Delaware corporation, issued a press release setting forth its financial results for the quarter ended March 31, 2024.”

XBP Global Holdings, Inc. reported the quarter ended March 31, 2024 results: revenue $40.4 million, net income $2.2 million.

“reference in such a filing. --- EX-99.1 (EX-99.1) --- ​ ​ XBP Europe Holdings, Inc. Reports First Quarter 2024 Results May 13, 2024 First Quarter Highlights ​ ● Revenue of $40.4 million, down 5.7% year-over-year (7.3% on a constant currency basis) ● Gross margin grew to 24.6%, a 270 bps increase sequentially and 250 bps increase year-over-year ● Net loss of $2.2”

Better Home & Finance Holding Co reported financial results for the first quarter ended March 31, 2024.

“On May 13, 2024, Better Home & Finance Holding Company (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended March 31, 2024.”

Terns Pharmaceuticals, Inc. reported the first quarter ended March 31, 2024 results: net income $22.4 million, EPS $(0.30).

“Net loss was $22.4 million for the quarter ended March 31, 2024”

Hyperfine, Inc. reported first quarter ended March 31, 2024 results: revenue $3.30 million, net income $9.85 million, EPS $0.14 per share. Guidance reaffirmed.

“Stroke Conference and 17 at International Society for Magnetic Resonance Medicine. First Quarter 2024 Financial Results • Revenues for the first quarter of 2024 were $3.30 million, up 25%, compared to $2.64 million in the first quarter of 2023. • Hyperfine, Inc. sold 13 commercial Swoop® systems in the first quarter of 2024. • Gross margin for the first”

BuzzFeed, Inc. reported financial results for the quarter ended March 31, 2024.

“On May 13, 2024, BuzzFeed, Inc. (the “Company”), issued a press release (the “Press Release”) announcing its financial results for the quarter ended March 31, 2024.”

Barinthus Biotherapeutics plc. reported financial results for first quarter of 2024.

“On May 13, 2024, Barinthus Biotherapeutics plc (the “Company”) announced its financial results for the first quarter of 2024 and provided an overview of the Company’s progress. The full text of the press release issued in connection with the update is furnished as Exhibit 99.1 to this Current Report on Form 8-K.”

Tourmaline Bio, Inc. reported first quarter ended March 31, 2024 results: net income Net loss was $13.3 million for the first quarter of 2024 and $7.5 million for the first quarter of 2023, resulting in ba.

“On May 13, 2024, Tourmaline Bio, Inc. (the “Company”) issued a press release announcing its recent business highlights and financial results for the quarter ended March 31, 2024.”

GRI Bio, Inc. reported first quarter ended March 31, 2024 results: net income Net loss was $1.9 million.

“GRI Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update”

Abacus Global Management, Inc. reported the quarterly period ended March 31, 2024 results: revenue $21.5 million, net income net loss of $1.3 million.

“Total revenue for the first quarter of 2024 more than doubled to $21.5 million, compared to $10.3 million in the prior-year period. The increase was primarily driven by higher active management revenue, increased capital deployed and more policies sold directly to third parties. o Total revenue from portfolio servicing segment for the first quarter of 2024 was $0.2 million, compared to $0.3 million in the prior-year period. - Originations capital deployment for the first quarter of 2024 were $33.3 million, compared to $34.4 million in the prior-year period; number of policy originations for the first quarter of 2024 grew 6% to 119, compared to 112 in the prior-year period. - GAAP net loss attributable to shareholders for the first quarter of 2024 was $1.3 million, compared to GAAP net income attributable to shareholders of $8.1 million in the prior-year period”

Benitec Biopharma Inc. reported third fiscal quarter ended March 31, 2024 results: revenue $0.

“Total Revenues for the quarter ended March 31, 2024, were $0 compared to $54,000 in licensing revenues collected for the quarter ended March 31, 2023.”

Jade Biosciences, Inc. reported quarter ended March 31, 2024 results: net income Net loss for the quarter ended March 31, 2024 was $23.2 million as compared to $16.5 million for the quarter ended March.

“Net loss for the quarter ended March 31, 2024 was $23.2 million as compared to $16.5 million for the quarter ended March 31, 2023.”

TMC the metals Co Inc. reported the first quarter ended March 31, 2024 results: net income Net loss of $25.2 million and net loss per share of $0.08, EPS $0.08 per share.

“TMC the metals company Inc. (Nasdaq: TMC) (“TMC” or “the Company”), an explorer of lower-impact battery metals from seafloor polymetallic nodules, today provided a corporate update and first quarter financial results for the period ending March 31, 2024.”

TScan Therapeutics, Inc. reported the first quarter ended March 31, 2024 results: revenue $0.6 million.

“• Long-term duration of response data for multiplex therapy anticipated in 2025. First Quarter 2024 Financial Results Revenue: Revenue for the first quarter of 2024 was $0.6 million, compared to $6.8 million for the first quarter of 2023. The decrease was primarily due to the timing of research activities pursuant to the Company’s collaboration agreements.”

Boundless Bio, Inc. reported the quarter ended March 31, 2024 results: net income $15.4 million.

“Boundless Bio Reports First Quarter 2024 Financial Results and Corporate Highlights”

Augmedix, Inc. reported first quarter ended March 31, 2024 results: revenue $13,471, net income $(6,499), EPS $(0.12).

“healthcare systems and clinicians who are helping us optimize our suite of solutions.” 1 Three Months Ended March 31, Financial Highlights: 2024 2023 Change Revenues $13,471 $9,628 40% Gross profit $6,341 $4,386 45% Gross margin 47.1 % 45.6 % 150 bps Net loss $(6,499) $(5,239) (24)% Loss per share $(0.12) $(0.14) 14% Adjusted EBITDA (non-GAAP)”

Unicycive Therapeutics, Inc. reported the three months ended March 31, 2024 results: net income Net loss attributable to common stockholders for the three months ended March 31, 2024 was $21.2 million, or $0.61 per s, EPS $0.61 per share of common stock.

“Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company” or “Unicycive”) , a clinical-stage biotechnology company developing therapies for patients with kidney disease , today announced its financial results for the three months ended March 31, 2024”

AVITA Medical, Inc. updated its first quarter ended March 31, 2024 guidance (lowered).

“On May 13, 2024, AVITA Medical, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2024.”

Turnstone Biologics Corp. reported first quarter ended March 31, 2024 results: net income Net loss was $19.6 million.

“On May 13, 2024, Turnstone Biologics Corp. (the “Company”) issued a press release announcing financial results for the fiscal quarter ended March 31, 2024”

Compass Therapeutics, Inc. reported the quarter ended March 31, 2024 results: net income $10.8 million, EPS $0.08 per share of common stock.

“On May 13, 2024, Compass Therapeutics, Inc. issued a press release announcing financial results for the quarter ended March 31, 2024.”

Allogene Therapeutics, Inc. reported financial results for the quarter ended March 31, 2024.

“Allogene Therapeutics, Inc. (the “Company”) provided a corporate update and announced its financial results for the quarter ended March 31, 2024 in the press release attached hereto as Exhibit 99.1”

Generation Bio Co. reported the quarter ended March 31, 2024 results: net income Net loss was $74.5 million, or $1.12 basic and diluted net loss per share.

“Generation Bio Co. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended March 31, 2024.”

Ensysce Biosciences, Inc. reported first quarter ended March 31, 2024 results: net income $3.1 million.

“On May 13, 2024, Ensysce Biosciences, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended March 31, 2024.”

Hyzon Motors Inc. reported first quarter ended March 31, 2024 results: revenue $10.0 million.

“power to decarbonize the most demanding industries, today announced its first quarter 2024 financial and operating results: Recent Highlights • First quarter 2024 Revenue of $10.0 million as compared to no revenue in the prior-year period, demonstrating material progress in customer acceptance and completion of commercial cycle • Announced Joint Development”

Akoya Biosciences, Inc. reported the first quarter ending March 31, 2024 results: revenue $18.4 million. Guidance lowered.

“(Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the first quarter ending March 31, 2024. ​ Business Highlights ​ ● Revenue was $18.4 million in the first quarter of 2024, compared to $21.4 million in the prior year period; a decrease of 14%. Reagents and services revenue continued to increase. ● Akoya announced the”

Virpax Pharmaceuticals, Inc. reported financial results for the three months ended March 31, 2024.

“Virpax ® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced its financial results for the three months ended March 31, 2024, and other recent developments.”

Datavault AI Inc. reported the quarter ended March 31, 2024 results: net income between $1.7 million and $3.7 million.

“For the quarter ended March 31, 2024, the Company’s net income (loss) is expected to be between $1.7 million and $3.7 million, as compared to net income (loss) of approximately $(921,000) for the prior-year period.”

Praxis Precision Medicines, Inc. reported the first quarter 2024 results: net income $39.6 million.

“Praxis Precision Medicines, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2024.”

SPRUCE BIOSCIENCES, INC. reported financial results for first quarter ended March 31, 2024.

“Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the first quarter ended March 31, 2024 and provided corporate updates.”

Fulcrum Therapeutics, Inc. reported first quarter of 2024 results: net income Net loss was $26.9 million for the three months ended March 31, 2024. Guidance reaffirmed.

“Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024”

UroGen Pharma Ltd. reported the first quarter ended March 31, 2024 results: revenue $18.8 million, net income net loss of $32.3 million or ($0.97) per basic and diluted share, EPS ($0.97) per basic and diluted share. Guidance reaffirmed.

“• Post-hoc analysis of OLYMPUS study for JELMYTO shows disease-free periods more than 47.8 months in LG-UTUC • JELMYTO ® demonstrated continued growth with net product sales of $18.8 million in Q1, compared with $17.2 million in Q1 2023 representing ~10% YoY growth • IND accepted for UGN-103, next-generation novel mitomycin-based formulation of UGN-102 to treat”

Verrica Pharmaceuticals Inc. reported first quarter ended March 31, 2024 results: revenue $3.2 million.

“Verrica recognized product revenue of $3.2 million in the first quarter of 2024.”

Moleculin Biotech, Inc. reported financial results for the quarter ended March 31, 2024.

“On May 13, 2024, Moleculin Biotech, Inc. issued an updated press release announcing its financial results for the quarter ended March 31, 2024 and recent operational highlights.”

Moleculin Biotech, Inc. reported financial results for the quarter ended March 31, 2024.

“On May 13, 2024, Moleculin Biotech, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2024 and recent operational highlights.”

Iterum Therapeutics plc reported first quarter ended March 31, 2024 results: net income $7.1 million.

“iterum Therapeutics plc issued a press release announcing its financial results for the first quarter ended March 31, 2024.”

Voyager Therapeutics, Inc. reported first quarter 2024 results: revenue $19.5 million, net income $11.3 million.

“INDs for the GBA1 and Friedreich’s Ataxia gene therapy programs in 2025. ​ First Quarter 2024 Financial Results ​ ● Collaboration Revenues: Voyager had collaboration revenue of $19.5 million for the first quarter of 2024, compared to $150.5 million for the same period in 2023. The decrease was primarily due to the first quarter 2023 recognition of $69.5 million from”

Senseonics Holdings, Inc. reported quarter ended March 31, 2024 results: revenue $5.1 million, net income Net loss was $18.9 million, or $0.03 per share, EPS $0.03 per share.

“Total revenue for the first quarter of 2024 was $5.1 million compared to $4.1 million for the first quarter of 2023.”

American Healthcare REIT, Inc. reported the three months ended March 31, 2024 results: EPS $(0.04) per basic and diluted share.

“Reported GAAP net loss attributable to common stockholders of $(0.04) per basic and diluted share for the three months ended March 31, 2024.”

Solana Co reported quarter ended March 31, 2024 results: revenue $135 thousand, net income net loss of $2.5 million, EPS $3.08 per share.

“Services to make PoNS available to federal healthcare systems, including the U.S. Department of Veterans Affairs (“VA”) and Department of Defense (“DoD”). ​ ● Q1 2024 revenue of $135 thousand, compared to $111 thousand in Q1 2023, reflecting increased product sales in both the U.S. and Canada . ​ ● Closed on $6.4 million public offering, raising net proceeds of”

Urgent.ly Inc. reported the first quarter ended March 31, 2024 results: revenue $40.1 million.

“executing our strategic priorities positions the company for long-term shareholder value creation,” said Matt Booth, CEO of Urgently. First Quarter 2024 Highlights: • Revenue of $40.1 million, a decrease of 19% year over year. • Gross profit of $9.4 million, an increase of 1% year over year. • Gross margin of 23% compared to 19% in the prior year period. • GAAP”

ATECH (PARENT) RESOLUTION CORP. reported third fiscal quarter for the period ended March 31, 2024 results: revenue $7.5 million.

“filters for mobile and other wireless applications, today announced third fiscal quarter results for the period ended March 31, 2024. Revenue was up 7% quarter-over-quarter to $7.5 million, including 13% growth sequentially in filter related revenue. Based on hundreds of active customers, robust activity in the sales and design win pipelines, and the semiconductor”

Theravance Biopharma, Inc. reported the first quarter of 2024 results: revenue Total revenue for the first quarter of 2024 was $14.5 million, net income Net loss was $11.7 million.

“Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results”

Vroom, Inc. reported first quarter ended March 31, 2024 results: net income $(44.7) million net loss from continuing operations.

“Vroom, Inc. (Nasdaq:VRM) today announced financial results for the first quarter ended March 31, 2024. HIGHLIGHTS OF FIRST QUARTER 2024 • $91.0 million cash and cash equivalents as of March 31, 2024 • $(44.7) million net loss from continuing operations • $(32.2) million Adjusted EBITDA”

FRACTYL HEALTH, INC. reported first quarter 2024 results: revenue Revenue in the quarter ended March 31, 2024.

“Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches for the treatment of obesity and type 2 diabetes (T2D), today reported its first quarter 2024 financial results”

Galera Therapeutics, Inc. reported first quarter ended March 31, 2024 results: net income $(4.4) million, or $(0.08) per share, EPS $(0.08) per share.

“Galera reported a net loss of $(4.4) million, or $(0.08) per share, for the first quarter of 2024, compared to a net loss of $(17.7) million, or $(0.50) per share, for the same period in 2023.”

Avalo Therapeutics, Inc. reported first quarter of 2024 results: net income net loss of $121.3 million.

“For the three months ended March 31, 2024, Avalo generated a net loss of $121.3 million.”